Fame and Mortality: Evidence from a Retrospective Analysis of Singers
November 26, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Northera
Synonyms :
droxidopa
Class :
Alpha/beta-agonist
Brand Name :
Northera
Synonyms :
droxidopa
Class :
Alpha/beta-agonist
Dosage Forms & StrengthsÂ
Capsule, Oral:Â
100 mgÂ
200 mgÂ
300 mgÂ
100
mg
Orally 
3 times a day
increase 100 mg every 48 hours (max. 600 mg 3 times a day)
No safe and efficacious dosing is availableÂ
Refer to adult dosingÂ
may increase the hypokalemic effect of thiazide diuretics
may increase the hypokalemic effect of thiazide diuretics
may have an increased tachycardic effect when combined with alpha-/beta-agonists
may have an increased tachycardic effect when combined with alpha-/beta-agonists
may have an increased tachycardic effect when combined with alpha-/beta-agonists
may have an increased tachycardic effect when combined with alpha-/beta-agonists
may have an increased tachycardic effect when combined with alpha-/beta-agonists
may enhance the vasopressor effect of alpha-/beta-agonists
may increase the hypertension effect
may have an increased tachycardic effect when combined with Alpha-/Beta-Agonists
may have an increased tachycardic effect when combined with Alpha-/Beta-Agonists
may have an increased tachycardic effect when combined with Alpha-/Beta-Agonists
may have an increased tachycardic effect when combined with Alpha-/Beta-Agonists
may have an increased tachycardic effect when combined with Alpha-/Beta-Agonists
may have an increased hypertensive effect when combined with alpha-/beta-agonists
may have an increased tachycardic effect when combined with alpha-/beta-agonists
may have an increased tachycardic effect when combined with alpha-/beta-agonists
may have an increased tachycardic effect when combined with alpha-/beta-agonists
may have an increased tachycardic effect when combined with alpha-/beta-agonists
may have an increased tachycardic effect when combined with alpha-/beta-agonists
may increase the vasoconstricting effect of hyaluronidase
May increase the adverse effect when combined
may enhance the serum concentration of each other when combined
may have an increased tachycardic effect when combined with alpha-/beta-agonists
may have an increased tachycardic effect when combined with alpha-/beta-agonists
may have an increased tachycardic effect when combined with alpha-/beta-agonists
may have an increased tachycardic effect when combined with alpha-/beta-agonists
ergot derivatives increase the effect of vasoconstriction of alpha beta agonists
ergot derivatives increase the effect of vasoconstriction of alpha beta agonists
ergot derivatives increase the effect of vasoconstriction of alpha beta agonists
ergot derivatives increase the effect of vasoconstriction of alpha beta agonists
ergot derivatives increase the effect of vasoconstriction of alpha beta agonists
may have an increased hypertensive effect when combined with alpha1-agonists
may have an increased hypertensive effect when combined with alpha1-agonists
may have an increased hypertensive effect when combined with alpha1-agonists
may have an increased hypertensive effect when combined with alpha1-agonists
may have an increased hypertensive effect when combined with alpha1-agonists
may increase the adverse effect of other beta2-agonists
may increase the adverse effect of other beta2-agonists
may increase the adverse effect of other beta2-agonists
may increase the adverse effect of other beta2-agonists
may increase the adverse effect of other beta2-agonists
may decrease the therapeutic effect when combined with radiopharmaceutical iobenguane products
may decrease the therapeutic effect when combined with radiopharmaceutical iobenguane products
may decrease the therapeutic effect when combined with radiopharmaceutical iobenguane products
may decrease the therapeutic effect when combined with radiopharmaceutical iobenguane products
may decrease the therapeutic effect when combined with radiopharmaceutical iobenguane products
may decrease the bronchodilatory effect
may decrease the bronchodilatory effect
may decrease the bronchodilatory effect
may decrease the bronchodilatory effect
may decrease the bronchodilatory effect
it increases the effect of hypertension of alpha 1-agonists
it increases the effect of hypertension of alpha 1-agonists
it increases the effect of hypertension of alpha 1-agonists
it increases the effect of hypertension of alpha 1-agonists
it increases the effect of hypertension of alpha 1-agonists
it increases the effect of hypertension of alpha 1-agonists
alpha-1 agonists decrease the efficacy of other alpha-1 agonists
alpha-1 agonists decrease the efficacy of other alpha-1 agonists
alpha-1 agonists decrease the efficacy of other alpha-1 agonists
alpha-1 agonists decrease the efficacy of other alpha-1 agonists
alpha-1 agonists decrease the efficacy of other alpha-1 agonists
they increase the effect of vasoconstriction of alpha-1 agonists
they increase the effect of vasoconstriction of alpha-1 agonists
they increase the effect of vasoconstriction of alpha-1 agonists
they increase the effect of vasoconstriction of alpha-1 agonists
they increase the effect of vasoconstriction of alpha-1 agonists
may increase the hypertension effect
may increase the toxic effect of beta2 agonists
may have an increased vasoconstricting effect when combined with alpha1-agonists
may have an increased vasoconstricting effect when combined with alpha1-agonists
may have an increased vasoconstricting effect when combined with alpha1-agonists
may have an increased vasoconstricting effect when combined with alpha1-agonists
may have an increased vasoconstricting effect when combined with alpha1-agonists
may decrease the therapeutic effect when combined with iobenguane products
may have an increased hypertensive effect when combined with alpha1-agonists
may have an increased hypertensive effect when combined with alpha1-agonists
may have an increased hypertensive effect when combined with alpha1-agonists
may have an increased hypertensive effect when combined with alpha1-agonists
may have an increased hypertensive effect when combined with alpha1-agonists
may have an increased hypertensive effect when combined with alpha1-agonists
may increase the hypertensive effect
may increase the hypertensive effect
may increase the hypertensive effect
may increase the hypertensive effect
may have an increased vasoconstricting effect when combined with alpha-/beta-agonists
may decrease the therapeutic effect when combined with iobenguane
may have an increased vasoconstricting effect when combined with alpha-/beta-agonists
may have an increased vasoconstricting effect when combined with alpha-/beta-agonists
may decrease the therapeutic effect of each other when combined
may have an increased hypertensive effect when combined with alpha-/beta-agonists
may increase the adverse effect of other beta2-agonists
may increase the adverse effect of other beta2-agonists
may increase the adverse effect of other beta2-agonists
may increase the adverse effect of other beta2-agonists
may increase the adverse effect of other beta2-agonists
may decrease the bronchodilatory effect when combined with Beta2-Agonists
may decrease the bronchodilatory effect when combined with Beta2-Agonists
may decrease the bronchodilatory effect when combined with Beta2-Agonists
may decrease the bronchodilatory effect when combined with Beta2-Agonists
may decrease the bronchodilatory effect when combined with Beta2-Agonists
may decrease the bronchodilatory effect when combined with Beta2-Agonists
may decrease the bronchodilatory effect when combined with Beta2-Agonists
may decrease the bronchodilatory effect when combined with Beta2-Agonists
Carbonic Anhydrase Inhibitors may increase the levels of serum concentration of Alpha-/Beta-Agonists
Carbonic Anhydrase Inhibitors may increase the levels of serum concentration of Alpha-/Beta-Agonists
Carbonic Anhydrase Inhibitors may increase the levels of serum concentration of Alpha-/Beta-Agonists
Carbonic Anhydrase Inhibitors may increase the levels of serum concentration of Alpha-/Beta-Agonists
Carbonic Anhydrase Inhibitors may increase the levels of serum concentration of Alpha-/Beta-Agonists
alpha1-Blockers may reduce the vasoconstricting effect of alpha-/Beta-agonist
bunazosin (Not available in the United States)
alpha1-Blockers may reduce the vasoconstricting effect of alpha-/Beta-agonist
alpha1-Blockers may reduce the vasoconstricting effect of alpha-/Beta-agonist
alpha1-Blockers may reduce the vasoconstricting effect of alpha-/Beta-agonist
alpha1-Blockers may reduce the vasoconstricting effect of alpha-/Beta-agonist
carbonic anhydrase inhibitors may enhance the levels of serum concentration of alpha-/beta-agonists
carbonic anhydrase inhibitors may enhance the levels of serum concentration of alpha-/beta-agonists
carbonic anhydrase inhibitors may enhance the levels of serum concentration of alpha-/beta-agonists
carbonic anhydrase inhibitors may enhance the levels of serum concentration of alpha-/beta-agonists
carbonic anhydrase inhibitors may enhance the levels of serum concentration of alpha-/beta-agonists
may decrease the bronchodilatory effect of beta-blockers
may decrease the bronchodilatory effect of beta-blockers
may have an increased hypertensive effect when combined with droxidopa
may have an increased hypertensive effect when combined with droxidopa
may have an increased hypertensive effect when combined with droxidopa
may have an increased hypertensive effect when combined with droxidopa
may have an increased hypertensive effect when combined with droxidopa
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may decrease the vasoconstricting effect when combined with alpha-/beta-agonists
may decrease the vasoconstricting effect when combined with alpha-/beta-agonists
may have an increased hypokalemic effect when combined with loop diuretics
may have an increased hypokalemic effect when combined with loop diuretics
may have an increased hypokalemic effect when combined with loop diuretics
it may diminish the excretion rate when combined with corifollitropin alfa resulting in an enhanced serum level
When droxidopa is used together with mebhydrolin, droxidopa's therapeutic effectiveness can be enhanced
may decrease the bronchodilatory effect of beta-blockers
may decrease the bronchodilatory effect of beta-blockers
may decrease the bronchodilatory effect of beta-blockers
may decrease the bronchodilatory effect of beta-blockers
may decrease the bronchodilatory effect of beta-blockers
may diminish the serum concentration when combined with urinary acidifying agents
may diminish the serum concentration when combined with urinary acidifying agents
may diminish the serum concentration when combined with urinary acidifying agents
may increase the levels of serum concentration of alpha-/beta-agonists
may increase the levels of serum concentration of alpha-/beta-agonists
may increase the levels of serum concentration of alpha-/beta-agonists
may increase the levels of serum concentration of alpha-/beta-agonists
may increase the levels of serum concentration of alpha-/beta-agonists
they increase the efficacy of alpha 1-agonists
it increases the effect of hypertension of alpha-1 agonists
may decrease the vasoconstriction effects
bunazosin (Not available in the United States)
may decrease the vasoconstriction effects
may decrease the vasoconstriction effects
may decrease the vasoconstriction effects
may decrease the vasoconstriction effects
may increase the hypertensive effect of Serotonin 5-HT1D Receptor Agonists
may decrease the vasoconstricting effect when combined with alpha1-agonists
may decrease the vasoconstricting effect when combined with alpha1-agonists
may have an increased hypertensive effect when combined with droxidopa
May increase the levels of serum concentration
May increase the levels of serum concentration
May increase the levels of serum concentration
May increase the levels of serum concentration
May increase the levels of serum concentration
may increase the vasopressor effect
may increase the vasopressor effect
may increase the vasopressor effect
may increase the vasopressor effect
may increase the vasopressor effect
may increase the vasopressor effect
may increase the vasopressor effect
may increase the vasopressor effect
may increase the vasopressor effect
may increase the vasopressor effect
may increase the vasopressor effect
may increase the vasopressor effect
may increase the vasopressor effect
may increase the vasopressor effect
may increase the vasopressor effect
may increase the vasopressor effect
may increase the vasopressor effect
may decrease the serum concentration
may decrease the serum concentration
may decrease the serum concentration
may have an increased hypertensive effect when combined with alpha-/beta-agonists
may have an increased hypertensive effect when combined with alpha-/beta-agonists
may decrease the vasoconstricting effect when combined with alpha-/beta-agonists
may have an increased hypertensive effect when combined with vasopressin
It may enhance the serum concentration when combined with alkalinizing agents
It may enhance the serum concentration when combined with alkalinizing agents
It may enhance the serum concentration when combined with alkalinizing agents
It may enhance the serum concentration when combined with alkalinizing agents
It may enhance the serum concentration when combined with alkalinizing agents
may enhance the serum concentration when combined with alpha-/beta-agonists
may enhance the serum concentration when combined with alpha-/beta-agonists
may enhance the serum concentration when combined with alpha-/beta-agonists
may enhance the serum concentration when combined with alpha-/beta-agonists
may enhance the serum concentration when combined with alpha-/beta-agonists
may have an increasingly adverse effect when combined with beta2-agonists
may have an increasingly adverse effect when combined with beta2-agonists
may have an increasingly adverse effect when combined with beta2-agonists
may have an increasingly adverse effect when combined with beta2-agonists
may have an increasingly adverse effect when combined with beta2-agonists
may have an increased hypertensive effect when combined with alpha1-agonists
may have an increased therapeutic effect when combined with alpha1-agonists
tricyclic antidepressants: they may increase the toxic effect of Beta2-Agonists
tricyclic antidepressants: they may increase the toxic effect of Beta2-Agonists
tricyclic antidepressants: they may increase the toxic effect of Beta2-Agonists
tricyclic antidepressants: they may increase the toxic effect of Beta2-Agonists
may reduce the vasoconstriction-inducing action
may reduce the vasoconstriction-inducing action
bunazosin (Not available in the United States)
may reduce the vasoconstriction-inducing action
may reduce the vasoconstriction-inducing action
may reduce the vasoconstriction-inducing action
could increase the vasopressor action
could increase the vasopressor action
could increase the vasopressor action
could increase the vasopressor action
could increase the vasopressor action
could increase the vasopressor action
may decrease the vasoconstricting effect when combined with alpha-/beta-agonists
bunazosin (Not available in the United States)
may decrease the vasoconstricting effect when combined with alpha-/beta-agonists
may decrease the vasoconstricting effect when combined with alpha-/beta-agonists
may decrease the vasoconstricting effect when combined with alpha-/beta-agonists
may decrease the vasoconstricting effect when combined with alpha-/beta-agonists
may increase the hypokalemic effect of beta2-agonists
may increase the hypokalemic effect of beta2-agonists
may increase the hypokalemic effect of beta2-agonists
may diminish the bronchodilatory effect when combined with beta2-agonists
may diminish the bronchodilatory effect when combined with beta2-agonists
may diminish the bronchodilatory effect when combined with beta2-agonists
may decrease the vasoconstricting effect when combined with beta/alpha-agonists
may decrease the vasoconstricting effect when combined with alpha-/beta-agonists
the therapeutic effects of droxidopa may be increased
Frequency defined:Â Â Â
>10%Â
Headache Â
1% to 10%Â
NauseaÂ
Dizziness Â
PostmarketingÂ
Chest painÂ
Abdominal painÂ
DiarrheaÂ
PancreatitisÂ
VomitingÂ
Behavioral changesÂ
Blurred visionÂ
hallucinationsÂ
Pregnancy consideration: Few adverse effects were reported in animal reproductive studies. Contradicted for pregnant women.Â
Lactation: excretion of droxidopa in breast milk is not known. Â
Pregnancy category:Â
Â
Patient information leafletÂ
Generic Name: DroxidopaÂ
Pronounced: droxidopa Â
Why do we use droxidopa?Â
Droxidopa is used for the treatment of hypotension.Â
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
